Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind study of VX-659 in triple combination with tezacaftor and ivacaftor in adults with cystic fibrosis
MOH_2017-08-16_000621Phase 2Not yet recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bamocaftor in cystic fibrosis (CF) (4 arms), sponsored by Vertex Pharmaceuticals. Primary endpoints: Safety and tolerability of VX-659 triple combination and Efficacy of VX-659 triple combination. Planned start Jul 2017; status: not yet recruiting.
02
Drugs
bamocaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on MOH_2017-08-16_000621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-08-16_000621.